drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00400 | DB12141 | 353 | 971 | [
"DDInter843",
"DDInter817"
] | Griseofulvin | Gilteritinib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
353,
24,
971
]
],
[
[
353,
24,
1135
],
[
1135,
23,
971
]
],
[
[
353,
24,
466
],
[
466,
62,
971
]
],
[
[
353,
63,
1023
],
[
1023,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Da... |
DB00352 | DB00939 | 482 | 1,338 | [
"DDInter1814",
"DDInter1135"
] | Tioguanine | Meclofenamic acid | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
482,
24,
1338
]
],
[
[
482,
21,
28709
],
[
28709,
60,
1338
]
],
[
[
482,
24,
850
],
[
850,
63,
1338
]
],
[
[
482,
63,
599
],
[
599,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"... | Tioguanine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Meclofenamic acid (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could ... |
DB01211 | DB01603 | 609 | 1,366 | [
"DDInter393",
"DDInter1195"
] | Clarithromycin | Meticillin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection. | Minor | 0 | [
[
[
609,
23,
1366
]
],
[
[
609,
62,
790
],
[
790,
40,
1366
]
],
[
[
609,
23,
339
],
[
339,
1,
1366
]
],
[
[
609,
62,
703
],
[
703,
1... | [
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Meticillin"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Piperacillin"
],
... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Piperacillin and Piperacillin (Compound) resembles Meticillin (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Bacampicillin and Bacampicillin (Compound) resembles Meticill... |
DB00193 | DB08816 | 534 | 578 | [
"DDInter1841",
"DDInter1802"
] | Tramadol | Ticagrelor | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
534,
24,
578
]
],
[
[
534,
6,
8374
],
[
8374,
45,
578
]
],
[
[
534,
21,
28646
],
[
28646,
60,
578
]
],
[
[
534,
25,
1011
],
[
1011,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Tramadol (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Tramadol may lead to a major... |
DB09045 | DB09128 | 52 | 1,241 | [
"DDInter607",
"DDInter231"
] | Dulaglutide | Brexpiprazole | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
52,
24,
1241
]
],
[
[
52,
62,
170
],
[
170,
24,
1241
]
],
[
[
52,
24,
1296
],
[
1296,
63,
1241
]
],
[
[
52,
63,
1179
],
[
1179,
... | [
[
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
],
... | Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec... |
DB04868 | DB12240 | 478 | 110 | [
"DDInter1293",
"DDInter1485"
] | Nilotinib | Polatuzumab vedotin | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
478,
24,
110
]
],
[
[
478,
25,
129
],
[
129,
23,
110
]
],
[
[
478,
63,
467
],
[
467,
24,
110
]
],
[
[
478,
74,
1419
],
[
1419,
2... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"E... | Nilotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin... |
DB00331 | DB09381 | 1,645 | 192 | [
"DDInter1164",
"DDInter678"
] | Metformin | Esterified estrogens | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Moderate | 1 | [
[
[
1645,
24,
192
]
],
[
[
1645,
24,
752
],
[
752,
23,
192
]
],
[
[
1645,
24,
1019
],
[
1019,
63,
192
]
],
[
[
1645,
63,
1685
],
[
1685,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and... |
DB01261 | DB12035 | 170 | 943 | [
"DDInter1679",
"DDInter1641"
] | Sitagliptin | Sarecycline | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
170,
24,
943
]
],
[
[
170,
24,
850
],
[
850,
24,
943
]
],
[
[
170,
63,
629
],
[
629,
24,
943
]
],
[
[
170,
24,
850
],
[
850,
24,... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00104 | DB15822 | 966 | 69 | [
"DDInter1323",
"DDInter1504"
] | Octreotide | Pralsetinib | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
966,
24,
69
]
],
[
[
966,
24,
124
],
[
124,
24,
69
]
],
[
[
966,
40,
1154
],
[
1154,
24,
69
]
],
[
[
966,
24,
124
],
[
124,
24,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Octreotide (Compound) resembles Pasireotide (Compound) and Pasireotide may cause a moderate interaction that coul... |
DB00421 | DB00687 | 443 | 870 | [
"DDInter1707",
"DDInter747"
] | Spironolactone | Fludrocortisone | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
443,
24,
870
]
],
[
[
443,
24,
1220
],
[
1220,
40,
870
]
],
[
[
443,
1,
1561
],
[
1561,
24,
870
]
],
[
[
443,
1,
1222
],
[
1222,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Spironolactone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when... |
DB00559 | DB00758 | 152 | 1,347 | [
"DDInter223",
"DDInter413"
] | Bosentan | Clopidogrel | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
152,
24,
1347
]
],
[
[
152,
6,
8374
],
[
8374,
45,
1347
]
],
[
[
152,
18,
5795
],
[
5795,
57,
1347
]
],
[
[
152,
21,
29215
],
[
29215,... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clopidogrel (Compound)
Bosentan (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is downregulated by Clopidogrel (Compound)
Bosentan (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Clopidogrel (Compound)
Bos... |
DB00814 | DB00860 | 1,171 | 891 | [
"DDInter1143",
"DDInter1513"
] | Meloxicam | Prednisolone | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1171,
24,
891
]
],
[
[
1171,
63,
175
],
[
175,
40,
891
]
],
[
[
1171,
63,
167
],
[
167,
1,
891
]
],
[
[
1171,
24,
617
],
[
617,
... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predniso... |
DB00029 | DB04932 | 25 | 1,564 | [
"DDInter99",
"DDInter491"
] | Anistreplase | Defibrotide | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Major | 2 | [
[
[
25,
25,
1564
]
],
[
[
25,
23,
297
],
[
297,
62,
1564
]
],
[
[
25,
24,
914
],
[
914,
24,
1564
]
],
[
[
25,
24,
41
],
[
41,
63,
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
... | Anistreplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may ... |
DB00029 | DB00554 | 25 | 1,027 | [
"DDInter99",
"DDInter1478"
] | Anistreplase | Piroxicam | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Moderate | 1 | [
[
[
25,
24,
1027
]
],
[
[
25,
24,
1171
],
[
1171,
1,
1027
]
],
[
[
25,
24,
222
],
[
222,
63,
1027
]
],
[
[
25,
64,
1578
],
[
1578,
2... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
[
... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam (Compound) resembles Piroxicam (Compound)
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that co... |
DB00792 | DB01320 | 832 | 651 | [
"DDInter1878",
"DDInter783"
] | Tripelennamine | Fosphenytoin | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
832,
24,
651
]
],
[
[
832,
40,
11234
],
[
11234,
40,
651
]
],
[
[
832,
63,
362
],
[
362,
1,
651
]
],
[
[
832,
24,
1264
],
[
1264,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Benzyl Benzoate"
],
[
"Benzyl Benzoate",
"{u}... | Tripelennamine (Compound) resembles Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) resembles Fosphenytoin (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Tripelennamine may cause a m... |
DB10316 | DB11793 | 334 | 738 | [
"DDInter1248",
"DDInter1297"
] | Mumps virus strain B level jeryl lynn live antigen | Niraparib | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Major | 2 | [
[
[
334,
25,
738
]
],
[
[
334,
64,
1213
],
[
1213,
24,
738
]
],
[
[
334,
25,
1619
],
[
1619,
63,
738
]
],
[
[
334,
25,
351
],
[
351,
... | [
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when ta... | Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening in... |
DB01246 | DB01276 | 820 | 123 | [
"DDInter45",
"DDInter706"
] | Alimemazine | Exenatide | A phenothiazine derivative that is used as an antipruritic. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
820,
24,
123
]
],
[
[
820,
63,
867
],
[
867,
24,
123
]
],
[
[
820,
74,
1630
],
[
1630,
24,
123
]
],
[
[
820,
24,
519
],
[
519,
2... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Alimemazine (Compound) resembles Perphenazine (Compound) and Alimemazine may cause a moderate interaction that c... |
DB00543 | DB00983 | 87 | 480 | [
"DDInter82",
"DDInter776"
] | Amoxapine | Formoterol | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
87,
24,
480
]
],
[
[
87,
24,
1148
],
[
1148,
63,
480
]
],
[
[
87,
6,
12523
],
[
12523,
45,
480
]
],
[
[
87,
21,
28762
],
[
28762,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Amoxapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound)
Amoxapine (Compo... |
DB00776 | DB06282 | 1,335 | 516 | [
"DDInter1360",
"DDInter1053"
] | Oxcarbazepine | Levocetirizine | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1335,
24,
516
]
],
[
[
1335,
63,
701
],
[
701,
24,
516
]
],
[
[
1335,
40,
21
],
[
21,
24,
516
]
],
[
[
1335,
24,
407
],
[
407,
6... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
]... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Oxcarbazepine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate intera... |
DB00005 | DB00011 | 1,057 | 1,451 | [
"DDInter687",
"DDInter944"
] | Etanercept | Interferon alfa-n1 | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Moderate | 1 | [
[
[
1057,
24,
1451
]
],
[
[
1057,
25,
450
],
[
450,
62,
1451
]
],
[
[
1057,
25,
310
],
[
310,
63,
1451
]
],
[
[
1057,
24,
238
],
[
238,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclophosphamide"
],
[
... | Etanercept may lead to a major life threatening interaction when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Interferon alfa-n1
Etanercept may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may c... |
DB00607 | DB00682 | 1,249 | 126 | [
"DDInter1256",
"DDInter1951"
] | Nafcillin | Warfarin | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
1249,
25,
126
]
],
[
[
1249,
6,
7950
],
[
7950,
45,
126
]
],
[
[
1249,
62,
168
],
[
168,
23,
126
]
],
[
[
1249,
64,
663
],
[
663,
... | [
[
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Nafcillin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Warfarin"
... | Nafcillin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Warfarin (Compound)
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin
Nafcillin may lead to a majo... |
DB00557 | DB11057 | 252 | 720 | [
"DDInter895",
"DDInter1223"
] | Hydroxyzine | Mineral oil | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
252,
24,
720
]
],
[
[
252,
24,
927
],
[
927,
63,
720
]
],
[
[
252,
24,
1151
],
[
1151,
24,
720
]
],
[
[
252,
25,
1069
],
[
1069,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Su... |
DB00421 | DB00486 | 443 | 1,614 | [
"DDInter1707",
"DDInter1253"
] | Spironolactone | Nabilone | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
443,
24,
1614
]
],
[
[
443,
24,
530
],
[
530,
1,
1614
]
],
[
[
443,
21,
28769
],
[
28769,
60,
1614
]
],
[
[
443,
63,
999
],
[
999,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Spironolactone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Nabilone (Compound)
Spironolactone may cause a... |
DB00533 | DB00860 | 1,416 | 891 | [
"DDInter1613",
"DDInter1513"
] | Rofecoxib | Prednisolone | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1416,
24,
891
]
],
[
[
1416,
24,
175
],
[
175,
40,
891
]
],
[
[
1416,
24,
167
],
[
167,
1,
891
]
],
[
[
1416,
63,
251
],
[
251,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predniso... |
DB00719 | DB11186 | 1,219 | 1,609 | [
"DDInter149",
"DDInter1427"
] | Azatadine | Pentoxyverine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1219,
24,
1609
]
],
[
[
1219,
24,
314
],
[
314,
24,
1609
]
],
[
[
1219,
63,
556
],
[
556,
24,
1609
]
],
[
[
1219,
25,
306
],
[
306,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Va... |
DB00390 | DB09472 | 1,252 | 1,383 | [
"DDInter554",
"DDInter1693"
] | Digoxin | Sodium sulfate | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Minor | 0 | [
[
[
1252,
23,
1383
]
],
[
[
1252,
1,
1482
],
[
1482,
23,
1383
]
],
[
[
1252,
25,
609
],
[
609,
24,
1383
]
],
[
[
1252,
23,
1311
],
[
1311,... | [
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interac... | Digoxin (Compound) resembles Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Digoxin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate d... |
DB01110 | DB15328 | 86 | 829 | [
"DDInter1209",
"DDInter1896"
] | Miconazole | Ubrogepant | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
86,
24,
829
]
],
[
[
86,
24,
1476
],
[
1476,
24,
829
]
],
[
[
86,
63,
883
],
[
883,
24,
829
]
],
[
[
86,
25,
1670
],
[
1670,
24,... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitin... |
DB01129 | DB04868 | 379 | 478 | [
"DDInter1559",
"DDInter1293"
] | Rabeprazole | Nilotinib | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
379,
24,
478
]
],
[
[
379,
23,
1468
],
[
1468,
63,
478
]
],
[
[
379,
6,
6017
],
[
6017,
45,
478
]
],
[
[
379,
21,
28963
],
[
28963,
... | [
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Rabeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
[
... | Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Rabeprazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Rabeprazole (Compound)... |
DB11828 | DB13179 | 1,406 | 68 | [
"DDInter1281",
"DDInter1882"
] | Neratinib | Troleandomycin | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
1406,
25,
68
]
],
[
[
1406,
63,
1413
],
[
1413,
23,
68
]
],
[
[
1406,
63,
973
],
[
973,
24,
68
]
],
[
[
1406,
24,
710
],
[
710,
... | [
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fexofenadine"
],
[
"Fexofe... | Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine and Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Pa... |
DB01432 | DB08946 | 857 | 512 | [
"DDInter368",
"DDInter962"
] | Cholestyramine | Iopanoic acid | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography. | Minor | 0 | [
[
[
857,
23,
512
]
],
[
[
857,
62,
1512
],
[
1512,
23,
122
],
[
122,
24,
512
]
],
[
[
857,
62,
1264
],
[
1264,
63,
1648
],
[
1648,
24,
... | [
[
[
"Cholestyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Cholestyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
],
... | Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Verapamil and Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Chole... |
DB00641 | DB06595 | 467 | 1,491 | [
"DDInter1675",
"DDInter1214"
] | Simvastatin | Midostaurin | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
467,
24,
1491
]
],
[
[
467,
24,
112
],
[
112,
23,
1491
]
],
[
[
467,
63,
289
],
[
289,
24,
1491
]
],
[
[
467,
24,
1017
],
[
1017,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin a... |
DB00377 | DB01267 | 1,494 | 519 | [
"DDInter1382",
"DDInter1381"
] | Palonosetron | Paliperidone | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
1494,
24,
519
]
],
[
[
1494,
24,
1664
],
[
1664,
1,
519
]
],
[
[
1494,
25,
924
],
[
924,
1,
519
]
],
[
[
1494,
6,
12523
],
[
12523,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Pal... |
DB00261 | DB11703 | 702 | 405 | [
"DDInter93",
"DDInter9"
] | Anagrelide | Acalabrutinib | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
702,
25,
405
]
],
[
[
702,
24,
383
],
[
383,
24,
405
]
],
[
[
702,
25,
982
],
[
982,
63,
405
]
],
[
[
702,
64,
1230
],
[
1230,
2... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Anagrelide may lead to a major life threatening interaction when taken with Ivosidenib an... |
DB01042 | DB14811 | 1,307 | 385 | [
"DDInter1144",
"DDInter979"
] | Melphalan | Isatuximab | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
1307,
24,
385
]
],
[
[
1307,
24,
1362
],
[
1362,
24,
385
]
],
[
[
1307,
63,
377
],
[
377,
24,
385
]
],
[
[
1307,
64,
770
],
[
770,
... | [
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may... |
DB04865 | DB06441 | 4 | 936 | [
"DDInter1335",
"DDInter283"
] | Omacetaxine mepesuccinate | Cangrelor | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Major | 2 | [
[
[
4,
25,
936
]
],
[
[
4,
64,
97
],
[
97,
24,
936
]
],
[
[
4,
24,
637
],
[
637,
63,
936
]
],
[
[
4,
63,
305
],
[
305,
24,
936... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
],
[
... | Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Oxaprozin and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Asparagin... |
DB00486 | DB14575 | 1,614 | 733 | [
"DDInter1253",
"DDInter674"
] | Nabilone | Eslicarbazepine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1614,
24,
733
]
],
[
[
1614,
24,
1264
],
[
1264,
24,
733
]
],
[
[
1614,
40,
530
],
[
530,
24,
733
]
],
[
[
1614,
63,
1594
],
[
1594,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exac... |
DB06595 | DB08899 | 1,491 | 129 | [
"DDInter1214",
"DDInter649"
] | Midostaurin | Enzalutamide | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
1491,
25,
129
]
],
[
[
1491,
63,
918
],
[
918,
1,
129
]
],
[
[
1491,
62,
1247
],
[
1247,
23,
129
]
],
[
[
1491,
24,
230
],
[
230,
... | [
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bica... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interac... |
DB00434 | DB00747 | 13 | 1,442 | [
"DDInter459",
"DDInter1647"
] | Cyproheptadine | Scopolamine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
13,
24,
1442
]
],
[
[
13,
63,
19
],
[
19,
24,
1442
]
],
[
[
13,
6,
4304
],
[
4304,
45,
1442
]
],
[
[
13,
21,
28766
],
[
28766,
6... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Cyproheptadine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Scopolamine (Compound)
Cyprohep... |
DB01268 | DB11866 | 1,151 | 1,068 | [
"DDInter1731",
"DDInter1618"
] | Sunitinib | Romosozumab | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
1151,
24,
1068
]
],
[
[
1151,
25,
1069
],
[
1069,
24,
1068
]
],
[
[
1151,
24,
1250
],
[
1250,
24,
1068
]
],
[
[
1151,
63,
770
],
[
770... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib"... | Sunitinib may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a m... |
DB01124 | DB06655 | 1,411 | 5 | [
"DDInter1828",
"DDInter1077"
] | Tolbutamide | Liraglutide | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1411,
24,
5
]
],
[
[
1411,
62,
1103
],
[
1103,
23,
5
]
],
[
[
1411,
63,
743
],
[
743,
23,
5
]
],
[
[
1411,
63,
1142
],
[
1142,
2... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
... | Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinop... |
DB00561 | DB13139 | 1,048 | 1,032 | [
"DDInter591",
"DDInter1063"
] | Doxapram | Levosalbutamol | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1048,
24,
1032
]
],
[
[
1048,
24,
22
],
[
22,
24,
1032
]
],
[
[
1048,
63,
1466
],
[
1466,
24,
1032
]
],
[
[
1048,
25,
1053
],
[
1053,
... | [
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
... | Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and... |
DB00348 | DB01211 | 254 | 609 | [
"DDInter1300",
"DDInter393"
] | Nitisinone | Clarithromycin | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
254,
24,
609
]
],
[
[
254,
21,
29488
],
[
29488,
60,
609
]
],
[
[
254,
63,
600
],
[
600,
23,
609
]
],
[
[
254,
24,
1247
],
[
1247,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Rash maculo-papular"
],
[
"Rash maculo-papular",
"{... | Nitisinone (Compound) causes Rash maculo-papular (Side Effect) and Rash maculo-papular (Side Effect) is caused by Clarithromycin (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects... |
DB00609 | DB01097 | 595 | 1,377 | [
"DDInter694",
"DDInter1033"
] | Ethionamide | Leflunomide | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
595,
25,
1377
]
],
[
[
595,
21,
28868
],
[
28868,
60,
1377
]
],
[
[
595,
24,
959
],
[
959,
24,
1377
]
],
[
[
595,
24,
1411
],
[
1411,
... | [
[
[
"Ethionamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Ethionamide",
"{u} (Compound) causes {v} (Side Effect)",
"Stomatitis"
],
[
"Stomatitis",
"{u} (Side Effect) is caused by {v} ... | Ethionamide (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Leflunomide (Compound)
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Lefl... |
DB00312 | DB09570 | 1,023 | 1,480 | [
"DDInter1423",
"DDInter1002"
] | Pentobarbital | Ixazomib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
1023,
24,
1480
]
],
[
[
1023,
24,
310
],
[
310,
24,
1480
]
],
[
[
1023,
24,
214
],
[
214,
63,
1480
]
],
[
[
1023,
1,
288
],
[
288,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib an... |
DB01155 | DB11113 | 872 | 657 | [
"DDInter813",
"DDInter307"
] | Gemifloxacin | Castor oil | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
872,
24,
657
]
],
[
[
872,
24,
927
],
[
927,
63,
657
]
],
[
[
872,
24,
1491
],
[
1491,
24,
657
]
],
[
[
872,
64,
891
],
[
891,
2... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and... |
DB00285 | DB00938 | 1,100 | 455 | [
"DDInter1927",
"DDInter1635"
] | Venlafaxine | Salmeterol | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1100,
24,
455
]
],
[
[
1100,
24,
688
],
[
688,
63,
455
]
],
[
[
1100,
6,
8374
],
[
8374,
45,
455
]
],
[
[
1100,
21,
29024
],
[
29024,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Venlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Venlafaxine (Com... |
DB00379 | DB00431 | 143 | 1,503 | [
"DDInter1206",
"DDInter1072"
] | Mexiletine | Lindane | Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Moderate | 1 | [
[
[
143,
24,
1503
]
],
[
[
143,
21,
28921
],
[
28921,
60,
1503
]
],
[
[
143,
63,
475
],
[
475,
24,
1503
]
],
[
[
143,
24,
1383
],
[
1383,
... | [
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Mexiletine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused ... | Mexiletine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Lindane (Compound)
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Lindane
Mexile... |
DB01222 | DB06674 | 617 | 908 | [
"DDInter246",
"DDInter837"
] | Budesonide | Golimumab | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
617,
25,
908
]
],
[
[
617,
23,
1193
],
[
1193,
62,
908
]
],
[
[
617,
62,
1461
],
[
1461,
23,
908
]
],
[
[
617,
63,
336
],
[
336,
... | [
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Budesonide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Golimumab
Budesonide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB00570 | DB11757 | 147 | 960 | [
"DDInter1936",
"DDInter994"
] | Vinblastine | Istradefylline | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Moderate | 1 | [
[
[
147,
24,
960
]
],
[
[
147,
24,
77
],
[
77,
24,
960
]
],
[
[
147,
63,
134
],
[
134,
24,
960
]
],
[
[
147,
24,
971
],
[
971,
63,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and... |
DB08868 | DB13915 | 1,011 | 689 | [
"DDInter737",
"DDInter146"
] | Fingolimod | Axicabtagene ciloleucel | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express ant... | Major | 2 | [
[
[
1011,
25,
689
]
],
[
[
1011,
64,
599
],
[
599,
24,
689
]
],
[
[
1011,
25,
270
],
[
270,
24,
689
]
],
[
[
1011,
63,
1430
],
[
1430,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab... | Fingolimod may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Fingolimod may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may caus... |
DB12001 | DB14575 | 564 | 733 | [
"DDInter7",
"DDInter674"
] | Abemaciclib | Eslicarbazepine | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
564,
24,
733
]
],
[
[
564,
63,
1101
],
[
1101,
23,
733
]
],
[
[
564,
63,
351
],
[
351,
24,
733
]
],
[
[
564,
64,
129
],
[
129,
2... | [
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and R... |
DB00242 | DB00848 | 1,064 | 281 | [
"DDInter392",
"DDInter1044"
] | Cladribine | Levamisole | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Major | 2 | [
[
[
1064,
25,
281
]
],
[
[
1064,
64,
599
],
[
599,
24,
281
]
],
[
[
1064,
25,
1683
],
[
1683,
63,
281
]
],
[
[
1064,
25,
597
],
[
597,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levamisole"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u}... | Cladribine may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Levamisole
Cladribine may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate ... |
DB00344 | DB00675 | 1,302 | 888 | [
"DDInter1543",
"DDInter1744"
] | Protriptyline | Tamoxifen | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
1302,
24,
888
]
],
[
[
1302,
24,
832
],
[
832,
40,
888
]
],
[
[
1302,
24,
543
],
[
543,
63,
888
]
],
[
[
1302,
24,
649
],
[
649,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Tamoxifen (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interacti... |
DB00357 | DB00705 | 1,051 | 441 | [
"DDInter71",
"DDInter496"
] | Aminoglutethimide | Delavirdine | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Moderate | 1 | [
[
[
1051,
24,
441
]
],
[
[
1051,
6,
10215
],
[
10215,
45,
441
]
],
[
[
1051,
21,
28709
],
[
28709,
60,
441
]
],
[
[
1051,
24,
303
],
[
303... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by... | Aminoglutethimide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Delavirdine (Compound)
Aminoglutethimide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate d... |
DB00501 | DB01390 | 752 | 1,117 | [
"DDInter380",
"DDInter1683"
] | Cimetidine | Sodium bicarbonate | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
752,
23,
1117
]
],
[
[
752,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
752,
63,
1018
],
[
1018,
23,
1117
]
],
[
[
752,
23,
108
],
[
108,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is ca... | Cimetidine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Sod... |
DB00029 | DB06603 | 25 | 39 | [
"DDInter99",
"DDInter1387"
] | Anistreplase | Panobinostat | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
25,
25,
39
]
],
[
[
25,
24,
578
],
[
578,
63,
39
]
],
[
[
25,
24,
383
],
[
383,
24,
39
]
],
[
[
25,
25,
4
],
[
4,
24,
39
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Tica... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysu... |
DB00526 | DB00544 | 1,555 | 970 | [
"DDInter1355",
"DDInter757"
] | Oxaliplatin | Fluorouracil | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Moderate | 1 | [
[
[
1555,
24,
970
]
],
[
[
1555,
6,
7950
],
[
7950,
45,
970
]
],
[
[
1555,
25,
945
],
[
945,
62,
970
]
],
[
[
1555,
24,
147
],
[
147,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Oxaliplatin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compoun... | Oxaliplatin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Fluorouracil (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Fluorouracil
Oxaliplatin may cause a m... |
DB01254 | DB05273 | 1,213 | 507 | [
"DDInter484",
"DDInter1638"
] | Dasatinib | Samarium (153Sm) lexidronam | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
1213,
25,
507
]
],
[
[
1213,
63,
789
],
[
789,
24,
507
]
],
[
[
1213,
24,
248
],
[
248,
24,
507
]
],
[
[
1213,
24,
270
],
[
270,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Valganci... |
DB00328 | DB00443 | 831 | 251 | [
"DDInter921",
"DDInter195"
] | Indomethacin | Betamethasone | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
831,
24,
251
]
],
[
[
831,
24,
617
],
[
617,
40,
251
]
],
[
[
831,
24,
870
],
[
870,
1,
251
]
],
[
[
831,
10,
11591
],
[
11591,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betam... |
DB00208 | DB01175 | 1,018 | 318 | [
"DDInter1804",
"DDInter672"
] | Ticlopidine | Escitalopram | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1018,
24,
318
]
],
[
[
1018,
25,
1230
],
[
1230,
1,
318
]
],
[
[
1018,
6,
8374
],
[
8374,
45,
318
]
],
[
[
1018,
21,
29276
],
[
29276,... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalo... | Ticlopidine may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Ticlopidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Ticlopidine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Si... |
DB00220 | DB00284 | 798 | 1,647 | [
"DDInter1276",
"DDInter11"
] | Nelfinavir | Acarbose | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Moderate | 1 | [
[
[
798,
24,
1647
]
],
[
[
798,
7,
2216
],
[
2216,
46,
1647
]
],
[
[
798,
7,
9384
],
[
9384,
57,
1647
]
],
[
[
798,
21,
28734
],
[
28734,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
]
],
[
[
"Nelfinavir",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (Compo... | Nelfinavir (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Acarbose (Compound)
Nelfinavir (Compound) upregulates TRIB3 (Gene) and TRIB3 (Gene) is downregulated by Acarbose (Compound)
Nelfinavir (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused... |
DB00470 | DB00726 | 530 | 1,164 | [
"DDInter601",
"DDInter1876"
] | Dronabinol | Trimipramine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
530,
24,
1164
]
],
[
[
530,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
530,
63,
508
],
[
508,
40,
1164
]
],
[
[
530,
25,
675
],
[
675,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Trimipramine (Comp... |
DB00635 | DB09054 | 1,573 | 384 | [
"DDInter1515",
"DDInter905"
] | Prednisone | Idelalisib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1573,
24,
384
]
],
[
[
1573,
24,
555
],
[
555,
23,
384
]
],
[
[
1573,
23,
307
],
[
307,
23,
384
]
],
[
[
1573,
63,
58
],
[
58,
2... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Prednisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil m... |
DB00557 | DB04843 | 252 | 1,511 | [
"DDInter895",
"DDInter1149"
] | Hydroxyzine | Mepenzolate | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
252,
24,
1511
]
],
[
[
252,
24,
537
],
[
537,
24,
1511
]
],
[
[
252,
63,
352
],
[
352,
24,
1511
]
],
[
[
252,
24,
649
],
[
649,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospiu... |
DB00758 | DB01404 | 1,347 | 757 | [
"DDInter413",
"DDInter820"
] | Clopidogrel | Ginseng | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
1347,
24,
757
]
],
[
[
1347,
62,
245
],
[
245,
24,
757
]
],
[
[
1347,
63,
25
],
[
25,
24,
757
]
],
[
[
1347,
24,
578
],
[
578,
6... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
... | Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anist... |
DB08865 | DB11691 | 1,593 | 1,499 | [
"DDInter448",
"DDInter1258"
] | Crizotinib | Naldemedine | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1593,
24,
1499
]
],
[
[
1593,
62,
307
],
[
307,
23,
1499
]
],
[
[
1593,
64,
932
],
[
932,
24,
1499
]
],
[
[
1593,
63,
723
],
[
723,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Crizotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Crizotinib may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a... |
DB06643 | DB12001 | 1,136 | 564 | [
"DDInter500",
"DDInter7"
] | Denosumab | Abemaciclib | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
1136,
24,
564
]
],
[
[
1136,
63,
58
],
[
58,
24,
564
]
],
[
[
1136,
24,
850
],
[
850,
24,
564
]
],
[
[
1136,
24,
1476
],
[
1476,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and ... |
DB01244 | DB08881 | 762 | 868 | [
"DDInter192",
"DDInter1925"
] | Bepridil | Vemurafenib | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
762,
25,
868
]
],
[
[
762,
6,
12523
],
[
12523,
45,
868
]
],
[
[
762,
21,
29106
],
[
29106,
60,
868
]
],
[
[
762,
62,
112
],
[
112,
... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Bepridil",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafeni... | Bepridil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Bepridil (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazo... |
DB01069 | DB09076 | 401 | 1,116 | [
"DDInter1533",
"DDInter1899"
] | Promethazine | Umeclidinium | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
401,
24,
1116
]
],
[
[
401,
24,
849
],
[
849,
24,
1116
]
],
[
[
401,
64,
1300
],
[
1300,
24,
1116
]
],
[
[
401,
63,
695
],
[
695,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Promethazine may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol ma... |
DB06636 | DB08820 | 1,623 | 1,478 | [
"DDInter980",
"DDInter997"
] | Isavuconazonium | Ivacaftor | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
1623,
25,
1478
]
],
[
[
1623,
25,
1135
],
[
1135,
62,
1478
]
],
[
[
1623,
63,
543
],
[
543,
24,
1478
]
],
[
[
1623,
24,
985
],
[
985,
... | [
[
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Isavuconazonium may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may c... |
DB01211 | DB06207 | 609 | 910 | [
"DDInter393",
"DDInter1667"
] | Clarithromycin | Silodosin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Major | 2 | [
[
[
609,
25,
910
]
],
[
[
609,
6,
8374
],
[
8374,
45,
910
]
],
[
[
609,
21,
28921
],
[
28921,
60,
910
]
],
[
[
609,
24,
1220
],
[
1220,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Silodosin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"... | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Silodosin (Compound)
Clarithromycin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Silodosin (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dexametha... |
DB00193 | DB09082 | 534 | 659 | [
"DDInter1841",
"DDInter1934"
] | Tramadol | Vilanterol | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
534,
24,
659
]
],
[
[
534,
24,
927
],
[
927,
63,
659
]
],
[
[
534,
25,
1069
],
[
1069,
24,
659
]
],
[
[
534,
24,
485
],
[
485,
2... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tramadol may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a ... |
DB04861 | DB06691 | 1,592 | 849 | [
"DDInter1271",
"DDInter1155"
] | Nebivolol | Mepyramine | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1592,
24,
849
]
],
[
[
1592,
6,
12523
],
[
12523,
45,
849
]
],
[
[
1592,
63,
770
],
[
770,
24,
849
]
],
[
[
1592,
24,
407
],
[
407,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nebivolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Nebivolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nebivolol may caus... |
DB00604 | DB00999 | 1,425 | 504 | [
"DDInter385",
"DDInter883"
] | Cisapride | Hydrochlorothiazide | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Major | 2 | [
[
[
1425,
25,
504
]
],
[
[
1425,
25,
1326
],
[
1326,
40,
504
]
],
[
[
1425,
25,
178
],
[
178,
1,
504
]
],
[
[
1425,
64,
323
],
[
323,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",... | Cisapride may lead to a major life threatening interaction when taken with Diclofenamide and Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Cisa... |
DB01357 | DB11921 | 890 | 1,019 | [
"DDInter1160",
"DDInter492"
] | Mestranol | Deflazacort | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
890,
24,
1019
]
],
[
[
890,
63,
170
],
[
170,
24,
1019
]
],
[
[
890,
1,
177
],
[
177,
24,
1019
]
],
[
[
890,
62,
1130
],
[
1130,
... | [
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Mestranol (Compound) resembles Estrone sulfate (Compound) and Estrone sulfate may cause a moderate interaction... |
DB00176 | DB00907 | 529 | 290 | [
"DDInter770",
"DDInter427"
] | Fluvoxamine | Cocaine (topical) | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Moderate | 1 | [
[
[
529,
24,
290
]
],
[
[
529,
6,
21998
],
[
21998,
45,
290
]
],
[
[
529,
21,
28741
],
[
28741,
60,
290
]
],
[
[
529,
24,
629
],
[
629,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Cocaine
Fluvoxamine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cocaine (Compound)
Fluvoxamine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Cocaine (Compou... |
DB01115 | DB01229 | 336 | 973 | [
"DDInter1291",
"DDInter1378"
] | Nifedipine | Paclitaxel (protein-bound) | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
336,
24,
973
]
],
[
[
336,
24,
310
],
[
310,
63,
973
]
],
[
[
336,
6,
7524
],
[
7524,
45,
973
]
],
[
[
336,
18,
2438
],
[
2438,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Nifedipi... |
DB09045 | DB09564 | 52 | 1,296 | [
"DDInter607",
"DDInter930"
] | Dulaglutide | Insulin degludec | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
52,
24,
1296
]
],
[
[
52,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
52,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
52,
24,
659
],
[
659,
... | [
[
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
... | Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and T... |
DB06402 | DB09078 | 1,079 | 1,228 | [
"DDInter1756",
"DDInter1036"
] | Telavancin | Lenvatinib | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
1079,
24,
1228
]
],
[
[
1079,
62,
112
],
[
112,
23,
1228
]
],
[
[
1079,
63,
609
],
[
609,
24,
1228
]
],
[
[
1079,
24,
603
],
[
603,
... | [
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Telavancin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Telavancin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and ... |
DB06723 | DB06799 | 115 | 212 | [
"DDInter58",
"DDInter1169"
] | Aluminum hydroxide | Methenamine | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Methenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane. In salt form it is used for the treatment of urinary tract infection (Example: methenamine hippurate which is the hippuric acid salt of methenamine). | Moderate | 1 | [
[
[
115,
24,
212
]
],
[
[
115,
25,
1475
],
[
1475,
63,
212
]
],
[
[
115,
62,
743
],
[
743,
23,
1283
],
[
1283,
24,
212
]
],
[
[
115,
... | [
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methenamine"
]
],
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium citrate"
],
... | Aluminum hydroxide may lead to a major life threatening interaction when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Methenamine
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Lisinopril an... |
DB00202 | DB11363 | 190 | 1,276 | [
"DDInter1716",
"DDInter39"
] | Succinylcholine | Alectinib | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
190,
24,
1276
]
],
[
[
190,
24,
61
],
[
61,
24,
1276
]
],
[
[
190,
24,
1476
],
[
1476,
63,
1276
]
],
[
[
190,
24,
61
],
[
61,
24... | [
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
]... | Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib... |
DB00030 | DB08869 | 1,685 | 162 | [
"DDInter934",
"DDInter1773"
] | Insulin human | Tesamorelin | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and... | Moderate | 1 | [
[
[
1685,
24,
162
]
],
[
[
1685,
24,
170
],
[
170,
24,
162
]
],
[
[
1685,
24,
1344
],
[
1344,
63,
162
]
],
[
[
1685,
24,
170
],
[
170,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tesamorelin"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tesamorelin
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozi... |
DB08904 | DB11817 | 375 | 1,259 | [
"DDInter342",
"DDInter165"
] | Certolizumab pegol | Baricitinib | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
375,
25,
1259
]
],
[
[
375,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
375,
62,
1461
],
[
1461,
23,
1259
]
],
[
[
375,
24,
949
],
[
949,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
... | Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vi... |
DB00776 | DB08899 | 1,335 | 129 | [
"DDInter1360",
"DDInter649"
] | Oxcarbazepine | Enzalutamide | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1335,
24,
129
]
],
[
[
1335,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1335,
21,
28703
],
[
28703,
60,
129
]
],
[
[
1335,
62,
608
],
[
608,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Oxcarbazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Oxcarbazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Oxcarbazepine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Oxcarbazepine may cause a minor interaction that can limit clinical effects when taken with Lidocaine ... |
DB01233 | DB11915 | 1,311 | 1,293 | [
"DDInter1197",
"DDInter1909"
] | Metoclopramide | Valbenazine | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
1311,
24,
1293
]
],
[
[
1311,
24,
516
],
[
516,
24,
1293
]
],
[
[
1311,
64,
401
],
[
401,
24,
1293
]
],
[
[
1311,
24,
283
],
[
283,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Metoclopramide may lead to a major life threatening interaction when taken with Promethazine and Pr... |
DB03904 | DB04896 | 1,574 | 901 | [
"DDInter1903",
"DDInter1220"
] | Urea | Milnacipran | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
1574,
24,
901
]
],
[
[
1574,
24,
41
],
[
41,
1,
901
]
],
[
[
1574,
24,
1383
],
[
1383,
63,
901
]
],
[
[
1574,
63,
1314
],
[
1314,
... | [
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"L... | Urea may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Urea may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction tha... |
DB00621 | DB00635 | 1,026 | 1,573 | [
"DDInter1357",
"DDInter1515"
] | Oxandrolone | Prednisone | A synthetic hormone with anabolic and androgenic properties. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1026,
24,
1573
]
],
[
[
1026,
63,
175
],
[
175,
40,
1573
]
],
[
[
1026,
24,
1220
],
[
1220,
40,
1573
]
],
[
[
1026,
40,
984
],
[
984,
... | [
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Predniso... |
DB00424 | DB00748 | 19 | 662 | [
"DDInter896",
"DDInter297"
] | Hyoscyamine | Carbinoxamine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
19,
24,
662
]
],
[
[
19,
63,
1594
],
[
1594,
24,
662
]
],
[
[
19,
24,
216
],
[
216,
24,
662
]
],
[
[
19,
21,
28921
],
[
28921,
6... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine a... |
DB00222 | DB00723 | 245 | 1,240 | [
"DDInter825",
"DDInter1176"
] | Glimepiride | Methoxamine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system. | Moderate | 1 | [
[
[
245,
24,
1240
]
],
[
[
245,
24,
170
],
[
170,
63,
1240
]
],
[
[
245,
63,
1179
],
[
1179,
24,
1240
]
],
[
[
245,
24,
1466
],
[
1466,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxamine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Methoxamine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro a... |
DB01206 | DB14761 | 37 | 242 | [
"DDInter1086",
"DDInter1578"
] | Lomustine | Remdesivir | An alkylating agent of value against both hematologic malignancies and solid tumors. | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
37,
24,
242
]
],
[
[
37,
64,
1377
],
[
1377,
24,
242
]
],
[
[
37,
24,
384
],
[
384,
24,
242
]
],
[
[
37,
63,
482
],
[
482,
24,
... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide... | Lomustine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause ... |
DB00035 | DB00844 | 1,314 | 314 | [
"DDInter507",
"DDInter1257"
] | Desmopressin | Nalbuphine | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
1314,
24,
314
]
],
[
[
1314,
24,
828
],
[
828,
40,
314
]
],
[
[
1314,
24,
421
],
[
421,
1,
314
]
],
[
[
1314,
24,
475
],
[
475,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Co... |
DB01263 | DB11837 | 859 | 1,297 | [
"DDInter1494",
"DDInter1351"
] | Posaconazole | Osilodrostat | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
859,
25,
1297
]
],
[
[
859,
25,
1135
],
[
1135,
23,
1297
]
],
[
[
859,
62,
112
],
[
112,
23,
1297
]
],
[
[
859,
24,
466
],
[
466,
... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{... | Posaconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may ... |
DB00843 | DB01087 | 479 | 1,520 | [
"DDInter583",
"DDInter1520"
] | Donepezil | Primaquine | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Minor | 0 | [
[
[
479,
23,
1520
]
],
[
[
479,
24,
1487
],
[
1487,
64,
1520
]
],
[
[
479,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
479,
21,
28722
],
[
2872... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primaquine"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Donepezil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Donepezil (Compound... |
DB00490 | DB01069 | 946 | 401 | [
"DDInter254",
"DDInter1533"
] | Buspirone | Promethazine | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
946,
24,
401
]
],
[
[
946,
25,
1264
],
[
1264,
63,
401
]
],
[
[
946,
24,
820
],
[
820,
63,
401
]
],
[
[
946,
24,
104
],
[
104,
2... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
... | Buspirone may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a mo... |
DB01211 | DB08881 | 609 | 868 | [
"DDInter393",
"DDInter1925"
] | Clarithromycin | Vemurafenib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
609,
25,
868
]
],
[
[
609,
6,
8374
],
[
8374,
45,
868
]
],
[
[
609,
7,
3553
],
[
3553,
46,
868
]
],
[
[
609,
18,
7451
],
[
7451,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Clarithromycin (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Vemurafenib (Compound)
Clarithromycin (Compound) downregulates PPIE (Gene) and PPIE (Gene) is upregulated by Vemurafenib (Compound)
Cla... |
DB00982 | DB11642 | 1,517 | 938 | [
"DDInter991",
"DDInter1480"
] | Isotretinoin | Pitolisant | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1517,
24,
938
]
],
[
[
1517,
63,
254
],
[
254,
24,
938
]
],
[
[
1517,
24,
617
],
[
617,
24,
938
]
],
[
[
1517,
24,
1619
],
[
1619,
... | [
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
... | Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Bu... |
DB01087 | DB01224 | 1,520 | 623 | [
"DDInter1520",
"DDInter1553"
] | Primaquine | Quetiapine | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1520,
24,
623
]
],
[
[
1520,
63,
827
],
[
827,
1,
623
]
],
[
[
1520,
64,
695
],
[
695,
1,
623
]
],
[
[
1520,
6,
12523
],
[
12523,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Primaquine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Primaquine (Compoun... |
DB00333 | DB09046 | 576 | 1,094 | [
"DDInter1166",
"DDInter1201"
] | Methadone | Metreleptin | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
576,
24,
1094
]
],
[
[
576,
24,
578
],
[
578,
24,
1094
]
],
[
[
576,
25,
1213
],
[
1213,
24,
1094
]
],
[
[
576,
25,
927
],
[
927,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
... | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Methadone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a m... |
DB00095 | DB10583 | 66 | 949 | [
"DDInter623",
"DDInter415"
] | Efalizumab | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
66,
24,
949
]
],
[
[
66,
63,
550
],
[
550,
24,
949
]
],
[
[
66,
24,
589
],
[
589,
24,
949
]
],
[
[
66,
25,
1377
],
[
1377,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Efalizumab may cause a moderate interaction that could exace... |
DB00331 | DB00620 | 1,645 | 175 | [
"DDInter1164",
"DDInter1855"
] | Metformin | Triamcinolone | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Moderate | 1 | [
[
[
1645,
24,
175
]
],
[
[
1645,
24,
1573
],
[
1573,
1,
175
]
],
[
[
1645,
62,
1103
],
[
1103,
1,
175
]
],
[
[
1645,
18,
5527
],
[
5527,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Metformin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) resembles Triamcinolone (Compound... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.